Why Science Applications International (SAIC) Is Down 11.9% After Cutting 2027 Revenue Outlook And What’s Next

Simply Wall St

Sat, February 14, 2026 at 4:10 PM GMT+9 3 min read

In this article:

SAIC

+3.79%

Earlier this week, Science Applications International Corporation updated its fiscal 2027 guidance, lowering expected revenue to US$7.00 billion–US$7.20 billion from US$7.35 billion–US$7.55 billion after unfavorable recompete decisions and procurement delays signaled an organic revenue decline.

The company is responding by prioritizing contracts with greater technology transformation potential, while maintaining its emphasis on margins and execution despite weaker revenue expectations.

We’ll now examine how this guidance cut, driven by procurement delays and contract losses, reshapes Science Applications International’s previously optimistic investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Science Applications International Investment Narrative Recap

To own Science Applications International today, you need to believe its shift toward higher value, technology transformation work can offset contract losses and procurement delays that are now pressuring revenue. The cut to fiscal 2027 guidance brings that risk front and center, since sustained delays and weaker recompete outcomes directly threaten the most important near term catalyst: a return to organic growth as existing backlog converts and new awards ramp.

The updated fiscal 2027 outlook, which now calls for revenue of US$7.00 billion to US$7.20 billion instead of US$7.35 billion to US$7.55 billion, is the announcement most directly tied to these risks. It crystallizes how procurement slippage and unfavorable awards can undermine prior optimism about a quick rebound, and it puts more weight on management’s plan to lean into mission and engineering work while protecting margins as a key catalyst from here.

Yet against that backdrop, investors should also weigh the risk that persistent procurement delays and tighter budgets could quietly reshape SAIC’s contract book in ways many shareholders are not fully focused on…

Read the full narrative on Science Applications International (it’s free!)

Science Applications International’s valuation narrative projects $7.7 billion in revenue and $344.8 million in earnings by 2028.

Uncover how Science Applications International’s forecasts yield a $113.38 fair value, a 31% upside to its current price.

Exploring Other Perspectives

SAIC 1-Year Stock Price Chart

Some of the most optimistic analysts were assuming SAIC could reach about US$8.5 billion of revenue and roughly US$438.7 million of earnings by 2028, while the latest guidance cut and contract losses highlight how sensitive that story is to procurement delays and budget friction. This shows you how far apart views can be and why it helps to compare several perspectives before deciding which version of SAIC’s future you find most convincing.

Story Continues  

Explore 4 other fair value estimates on Science Applications International - why the stock might be worth over 2x more than the current price!

Build Your Own Science Applications International Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Science Applications International research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.

Our free Science Applications International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Science Applications International's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don’t last. These are today’s most promising picks. Check them out now:

Find 53 companies with promising cash flow potential yet trading below their fair value.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include SAIC.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info